Physician profile
Charles Lanning
NPI 1760405500
$1,921.98
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $480 · 2020: $405 · 2021: $789 · 2022: $248.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.74 | 2019-2022 | |
| Astellas Pharma US INC | $174.22 | 2019-2021 | |
| Daiichi Sankyo INC. | $173.30 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $111.45 | 2021-2022 | |
| Channel Medsystems, INC. | $92.45 | 2022 | |
| Merck Sharp & Dohme LLC | $85.23 | 2019-2021 | |
| Boston Scientific Corporation | $82.82 | 2019-2021 | |
| Allergan, INC. | $80.61 | 2020 | |
| Roche Diagnostics Corporation | $66.45 | 2019-2021 | |
| Intuitive Surgical, INC. | $56.34 | 2021 | |
| Pfizer INC. | $52.94 | 2020-2022 | |
| Corcept Therapeutics | $47.39 | 2019 | |
| Mylan Pharmaceuticals INC. | $47.38 | 2019-2021 | |
| Coloplast Corp | $44.61 | 2019-2021 | |
| Coopersurgical, INC. | $43.06 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $39.40 | 2021 | |
| Amgen INC. | $38.56 | 2019-2021 | |
| Organon LLC | $30.56 | 2021-2022 | |
| Evofem Biosciences, INC. | $28.23 | 2021 | |
| Duchesnay USA Incorporated | $27.74 | 2019 | |
| Therapeuticsmd, INC. | $24.17 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.82 | 2022 | |
| Myovant Sciences INC. | $17.78 | 2022 | |
| Avanos Medical | $16.02 | 2019 | |
| Vertical Pharmaceuticals, LLC | $14.03 | 2019 | |
| Amag Pharmaceuticals, INC. | $12.79 | 2019 | |
| Olympus America INC. | $11.89 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Lanning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.